US Stock MarketDetailed Quotes
SXTP 60 Degrees Pharmaceuticals
- 1.090
- -0.310-22.14%
Close Jan 8 16:00 ET
- 1.100
- +0.010+0.92%
Post 20:01 ET
2.50MMarket Cap-0.34P/E (TTM)
1.600High1.060Low14.58MVolume1.490Open1.400Pre Close30.79MTurnover757.53%Turnover RatioLossP/E (Static)2.30MShares12.24052wk High-0.71P/B2.10MFloat Cap0.70252wk Low--Dividend TTM1.92MShs Float103.800Historical High--Div YieldTTM38.57%Amplitude0.701Historical Low2.111Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
60 Degrees Pharmaceuticals Stock Forum
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. Microti) Babesiosis
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, ...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
$60 Degrees Pharmaceuticals (SXTP.US)$
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
Monday, 23rd December at 8:57 am
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company, and Tufts Medical Center ("Tufts MC"), a leading academic medical center, today announced the signi...
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital
Wednesday, 11th December at 8:56 am
• The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.
• The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley, M.D., and David Leaf, M.D.
• The double-blind, placebo-controlled trial will examine ou...
no matter how much it is rising now, many former traders of this stock have lost confidence in this stock because it had dropped more and more every day! when people were holding the shares and they bought at 1.5+ , it had decreased to 1, then 0.95, then it suddenly rised to 1.38 for a few seconds, most of the traders did not had the chance to sell their shares because it only last for a few seconds! then it dropped to about 1 again, then 0.9, then 0.8.5, an...
No comment yet